Breast Cancer Trial, Recruiting NCT07502352 Sponsor: University of Miami Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07502352
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 50 years of age or older
  • People who can speak and read English or Spanish at around a 6th-grade level
  • People who have been diagnosed with Stage I, II, or III breast cancer that is hormone receptor-positive (meaning it responds to estrogen and/or progesterone) and HER2-negative, and who have finished their main cancer treatment between 3 and 12 months ago
  • People who are post-menopausal, meaning it has been more than 12 months since their last period
  • People experiencing elevated emotional distress related to their cancer, as measured by a specific questionnaire or assessed by the research team
  • People who, if taking antidepressants or anti-anxiety medications, have been on a stable dose for more than 2 months
  • People who are currently taking a hormone-blocking medication as part of their ongoing breast cancer treatment (called Adjuvant Endocrine Therapy)
  • People who may or may not have received chemotherapy or radiation as part of their main cancer treatment

Who may not be able to join:

  • People who are unable or unwilling to give formal consent to participate
  • People diagnosed with metastatic breast cancer, HER2-positive breast cancer, or Triple Negative breast cancer
  • People who had another cancer diagnosis (other than certain common skin cancers) within the 2 years before their current breast cancer diagnosis
  • People with an active and untreated serious mental health condition, such as schizophrenia, psychosis, bipolar disorder, substance use disorder, panic disorder, or PTSD
  • People with certain ongoing or serious medical conditions known to affect the immune system, such as HIV, lupus, rheumatoid arthritis, hepatitis, multiple sclerosis, Graves' disease, chronic fatigue syndrome, or fibromyalgia (confirm with trial site for the full list; note that a history of heart disease such as stroke, heart attack, or heart failure does not appear to be automatically disqualifying)
  • People with significant memory or thinking difficulties, as measured by a specific cognitive screening test (confirm with trial site)
  • People who received immunotherapy as part of their cancer treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Antoni, Ph.D, University of Miami

Phone: (305) 284-2220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Psychological Adaptation measured by Cancer-Specific Distress (IES-Intrusion); Change in Immune Cell Senescence measured by Lymphocyte Metabolic Function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov